SCHEMBL234906

SCHEMBL234906

CC(C)(C)c1cc2ncc3cc(-c4ccsc4)c(=O)[nH]c3n2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.36
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
ALDH1A1 P00352 2/20 0.34
USP2 O75604 1/20 0.34
PKM P14618 1/20 0.34
FYN P06241 1/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
POLB P06746 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CYP2A6 P11509 1/20 0.32
PDE10A Q9Y233 1/20 0.32
GFER P55789 1/20 0.32
GRIN2D O15399 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238239 0.88 BTK (0.38) BTKCDK5CDK5R1ALDH1A1USP2
SCHEMBL236540 0.85 AURKA (0.38) ALDH1A1PKMRAB9ANPC1SMN1; SMN2
SCHEMBL238226 0.84 KDM5B (0.38) BTKCDK5CDK5R1ALDH1A1USP2
SCHEMBL234907 0.81 PLAT (0.36) BTKALDH1A1FYNKMT2AKDM4E
SCHEMBL237827 0.79 NPC1 (0.44) CDK5CDK5R1ALDH1A1FYNRAB9A
SCHEMBL236019 0.78 PLAT (0.35) BTKNPC1ADORA3
SCHEMBL238211 0.77 CYP11B1 (0.35) BTKALDH1A1FYNRAB9ANPC1
SCHEMBL238920 0.70 NPC1 (0.56) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL237778 0.70 POLB (0.47) ALDH1A1USP2RAB9ANPC1SMN1; SMN2
SCHEMBL236940 0.70 KDR (0.41) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 BTK 221/4885CDK5 70/4885CDK5R1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.